Public disclosure of inside information according to article 17 MAR
Heidelberg (pta037/29.04.2021/13:40) - The Management Board of 2invest AG (Frankfurt: 2INV; ISIN: DE000A3H3L44; Prime Standard) resolved today, with the approval of the Supervisory Board, to apply shortly to the Management Board of the Frankfurt Stock Exchange for the revocation of the admission of the shares of 2invest AG to the sub-segment of the regulated market with additional post-admission obligations (Prime Standard) in accordance with section 57 of the Exchange Rules of the Frankfurt Stock Exchange.
Due to the change of the stock exchange segment, the aforementioned additional post-admission obligations no longer apply. These include, for example, the requirement to fulfil transparency obligations in English. This significantly reduces the costs associated with the listing for the company. The change of segment does not affect the admission of the shares of 2invest AG to trading on the regulated market of the Frankfurt Stock Exchange (General Standard). The tradability will not be restricted.
The revocation of admission shall become effective upon expiry of three months after publication of the revocation decision by the Management Board of the Frankfurt Stock Exchange on the Internet (www.deutsche-boerse.com).
*** End of the ad hoc announcement***
For further information please contact:
2invest AG
Hansjörg Plaggemars, Board of Directors
Email: h.plaggemars@2invest-ag.com
Tel: +49 06221 649240
Email: info@2invest-ag.com
(end)
emitter: 2invest AG
address: Ziegelhäuser Landstr. 3, 69120 Heidelberg
country: Germany
contact person: Hansjörg Plaggemars
phone: +49 6221 649 240
e-mail: info@2invest-ag.com
website: www.2invest-ag.com
ISIN(s): DE000A3H3L44 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf; open market in Berlin, Tradegate
[ source: http://www.pressetext.com/news/20210429037 ]
Attachments
- Original document
- Permalink
Disclaimer
4basebio AG published this content on 29 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2021 15:07:03 UTC.